In patients with clinically localized PCa, a low PSMA PET/CT SUV max and a low percentage of GS 4+4 cores to cancer bearing cores predict an increased likelihood of downgrading and thus reclassification to intermediate-risk disease according to EAU and NCCN guidelines. The gene discussed is FOLH1; the disease is cancer.